ClinicalTrials.gg

Program

progerinin

Its studies are led by PRG Science & Technology.

Furthest: phase 2, since Mar 31, 20233 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PRG Science & Technology31 open or runningphase 2since Mar 31, 2023Aug 6, 2020Dec 2027phase 2 · NCT05847179

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2020First study: phase 1 study in ProgeriaFirst studyNCT04512963 · 64 enrolled · United States
  2. Mar 31, 2023Phase 2 study in Werner SyndromeNCT05847179 · 5 planned · United States
  3. Dec 11, 2024Phase 2 study in ProgeriaNCT06775041 · 10 enrolled · United States

Ahead

  1. Dec 2027Primary completion: phase 2 study in Werner SyndromeNCT05847179

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06775041Progeria · United States2CompletedMar 30, 202610
NCT05847179Werner Syndrome · United States2RecruitingDec 20275
NCT04512963Progeria · United States1CompletedJul 27, 202164

How it is read

Names in the registry

  • “Progerinin”, 3 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.